Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dr. Wu Skincare Co., Ltd. (6523.TWO)
Taipei, TW
Dr. Wu Skincare Co., Ltd. is a company that develops and distributes a broad spectrum of skincare and cosmetic products, serving both the Taiwanese domestic market and an international clientele. Their comprehensive product range includes facial cleansers, treatment masks, toners, concentrated serums, various moisturizers (lotions, creams, and gels), UV/DD creams for sun protection, and specialized eye care, alongside general makeup and body care items. Furthermore, the company formulates targeted solutions for specific skin concerns such as acne and pore issues, blackheads, dry skin conditions, visible signs of aging, dull or spotty complexions, sensitive skin, brightening, and emergency skin care. These products are made available through an extensive retail network comprising approximately 2,000 sales locations in diverse regions including Mainland China, Myanmar, Thailand, Malaysia, Singapore, Canada, Vietnam, the Philippines, and Japan. Founded in 2003, Dr. Wu Skincare Co., Ltd. is headquartered in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50% | +0.61% | -15.00% | -16.79% | -16.09% | -16.79% | -28.81% | -22.67% | +29.74% | -58.46% | -46.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%-5.9% Q1'26: -20.4% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%-26.5% Q1'26: -45.2% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+31.1% Q1'26: +74.7% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+37.9% ★ Q1'26: +32.0% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+62.8% ★ Q1'26: +51.1% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%-0.4% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.09× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.15B
est: 1.15B (0.0%)
|
936.92M
est: 979.00M (-4.3%)
|
963.00M
est: 1.00B (-4.1%)
|
1.01B
est: 1.01B (+0.2%)
|
764.63M
est: 765.00M (0.0%)
|
1.11B
est: 1.11B (+0.0%)
|
926.79M
est: 1.24B (-25.1%)
|
1.14B
est: 1.10B (+3.0%)
|
1.24B
est: 1.22B (+1.8%)
|
1.17B
est: 1.30B (-10.2%)
|
| EBITDA |
388.59M
est: 638.69M (-39.2%)
|
152.59M
est: 543.24M (-71.9%)
|
92.31M
est: 557.09M (-83.4%)
|
261.17M
est: 561.55M (-53.5%)
|
807.98M
est: 424.50M (+90.3%)
|
385.02M
est: 613.72M (-37.3%)
|
434.30M
est: 686.96M (-36.8%)
|
535.46M
est: 612.61M (-12.6%)
|
604.58M
est: 527.49M (+14.6%)
|
452.53M
est: 562.51M (-19.6%)
|
| EBIT |
374.87M
est: 630.26M (-40.5%)
|
148.23M
est: 536.08M (-72.3%)
|
70.81M
est: 549.75M (-87.1%)
|
229.23M
est: 554.15M (-58.6%)
|
794.09M
est: 418.90M (+89.6%)
|
372.79M
est: 605.62M (-38.4%)
|
424.61M
est: 677.90M (-37.4%)
|
526.04M
est: 604.53M (-13.0%)
|
596.16M
est: 516.54M (+15.4%)
|
442.88M
est: 550.84M (-19.6%)
|
| Net Income |
312.12M
est: 252.02M (+23.8%)
|
127.26M
est: 139.76M (-8.9%)
|
24.84M
est: 132.88M (-81.3%)
|
191.80M
est: 134.41M (+42.7%)
|
661.11M
est: 184.47M (+258.4%)
|
296.24M
est: 305.40M (-3.0%)
|
339.98M
est: 337.93M (+0.6%)
|
424.73M
|
476.25M
est: 457.87M (+4.0%)
|
350.27M
est: 467.33M (-25.0%)
|
| SGA |
399.97M
est: 340.37M (+17.5%)
|
437.31M
est: 289.50M (+51.1%)
|
504.09M
est: 296.89M (+69.8%)
|
447.91M
est: 299.26M (+49.7%)
|
266.41M
est: 226.22M (+17.8%)
|
307.89M
est: 327.06M (-5.9%)
|
278.22M
est: 366.09M (-24.0%)
|
314.93M
est: 326.47M (-3.5%)
|
341.04M
est: 352.81M (-3.3%)
|
368.92M
est: 376.24M (-1.9%)
|
| EPS |
7.06
est: 5.58 (+26.6%)
|
2.78
est: 3.09 (-10.1%)
|
0.55
est: 2.94 (-81.3%)
|
4.26
est: 2.98 (+43.2%)
|
14.68
est: 4.08 (+259.5%)
|
6.58
est: 6.76 (-2.7%)
|
7.55
est: 7.48 (+0.9%)
|
9.43
|
10.58
est: 10.17 (+4.0%)
|
7.78
est: 10.38 (-25.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 2.8K | 0.42% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 22.9K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 25.6K | 0.28% |
| 4 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 33.8K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fay Huang | Director of Marketing Planning | — | female |
| Jeremy Chiu | Sales Management Director | — | male |
| Lin Yuhui | Accounting Supervisor | — | female |
| Ling-Ling Lee | President | — | female |
| Xuan Hu Hsing | Senior Manager of Procurement Department, Administration Manager & Director | — | male |
| Yi-Ju Wu | Chief Executive Officer, GM & Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6523.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
